Furthermore, the inhibition of ULK1, in combination with sorafenib, significantly suppressed the HCC progression as compared with sorafenib alone or vehicle treatment alone (Xue et al., 2020). This evidence concerns the gene ULK1 and hepatocellular carcinoma.